Galderma

Galderma has received approval in the European Union for the hyaluronic acid filler Restylane Shaype for the temporary augmentation and shaping of the chin area. The product is injected deep onto the bone and is based on Nasha‑HD technology. In a 12‑month study, 83% of participants reported improved chin structure and definition after three months, and 84% said they would choose to be treated again. Restylane Shaype is already approved in Canada and Brazil, and the EU approval marks another regulatory milestone for the Restylane portfolio. » Plus sur finanzen.net

A year ago Galderma shares closed at CHF 130.40. A CHF 1,000 investment would have bought 7.669 shares, whose closing price on 06.08.2026 of CHF 178.25 per share corresponds to a total value of CHF 1,366.95 (+36.69%). Galderma is valued at CHF 41.59 billion; the share was first traded on 22.03.2024 at CHF 61.00. » Plus sur finanzen.net

Galderma reported net sales of $3.13 billion for H1 2026 and currency‑adjusted growth of 24.6%, both above consensus expectations. Adjusted EBITDA also beat estimates, and the revenue-growth forecast for 2026 was raised to 19–21%, driven by Nemluvio’s performance. However, the stock fell on profit‑taking, valuation doubts and continued FDA setbacks with Relfydess, which point to manufacturing and quality risks. » Plus sur de.investing.com